Zaltrap

RSS

aflibercept

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Zaltrap. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Zaltrap.

For practical information about using Zaltrap, patients should read the package leaflet or contact their doctor or pharmacist.

This EPAR was last updated on 21/12/2022

Authorisation details

Product details
Name
Zaltrap
Agency product number
EMEA/H/C/002532
Active substance
aflibercept
International non-proprietary name (INN) or common name
aflibercept
Therapeutic area (MeSH)
Colorectal Neoplasms
Anatomical therapeutic chemical (ATC) code
L01XX44
Publication details
Marketing-authorisation holder
Sanofi Winthrop Industrie
Revision
13
Date of issue of marketing authorisation valid throughout the European Union
01/02/2013
Contact address

82 Avenue Raspail
94250 Gentilly
FRANCE

Product information

15/12/2022 Zaltrap - EMEA/H/C/002532 - II/0067/G

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Antineoplastic agents

Therapeutic indication

Treatment of metastatic colorectal cancer (MCRC).

Assessment history

How useful was this page?

Add your rating
Average
1 rating